Tonix Pharmaceuticals Holding Corp. (TNXP): Shareholders' Equity
$245.15M
As of 2025-12-31
$222.28M
As of 2026-06-30
+5.8%
3-year compound annual growth
+22.8%
5-year compound annual growth
+19.8%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $245.15M | +75.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $139.56M | +32.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $105.53M | -49.1% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $207.18M | -5.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $218.72M | +149.5% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $87.65M | +830.7% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $9.42M | -60.2% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $23.66M | -3.9% | 2020-03-24, Balance as of period end |
| 2017-12-31 | $24.62M | -2.9% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $25.36M | -37.0% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $40.26M | +11.6% | 2017-04-13, Balance as of period end |
| 2014-12-31 | $36.09M | +454.2% | 2016-03-03, Balance as of period end |
| 2013-12-31 | $6.51M | +579.0% | 2016-03-03, Balance as of period end |
| 2012-12-31 | $959.0K | n/m | 2014-03-28, Balance as of period end |
| 2011-12-31 | -$2.45M | n/m | 2014-03-28, Balance as of period end |
| 2010-12-31 | -$175.0K | n/m | 2014-03-28, Balance as of period end |
| 2009-12-31 | -$537.0K | n/m | 2014-03-28, Balance as of period end |
| 2008-12-31 | -$545.0K | n/m | 2014-03-28, Balance as of period end |
| 2007-12-31 | -$415.0K | n/a | 2014-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $205.57M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.47M | -18.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $53.41M | -55.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $76.58M | -21.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $68.64M | -47.8% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$18.69M | n/m |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗